Related Experiment Video

Updated: Jun 20, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.2K

Antiviral therapy for patients with COVID-19: mix and match

Karolina Akinosoglou1, Charalambos Gogos1

  • 1Department of Medicine, University of Patras, Rio 26504, Greece.

The Lancet. Infectious Diseases
|July 18, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

530
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

13.8K

Related Experiment Videos

Last Updated: Jun 20, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.2K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

530
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

13.8K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

45.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.8K
Viral Recombination00:57

Viral Recombination

23.4K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
23.4K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.8K

Articles linked to this work by shared authors, journal, and citation graph.

Antimicrobial Resistance in Major Gram-Positive Pathogens: Beyond the Vancomycin Border.

Antibiotics (Basel, Switzerland)·2026

Oral Lesions in People Living with HIV: The Lining HIV Study.

Pathogens (Basel, Switzerland)·2026

Dietary Supplements and Oxidative Stress Management in Young Adults Following Intensive Exercise: A Systematic Review.

Sports (Basel, Switzerland)·2026

Evaluating rapid diagnostics for severe infections and sepsis: A systematic review and meta-analysis on behalf of the Hellenic Microbiological Society and the Hellenic Society of Chemotherapy.

International journal of antimicrobial agents·2026

An update on beta-lactam-beta-lactamase inhibitor combinations for the treatment of carbapenem-resistant Gram-negative pathogens.

Expert opinion on drug metabolism & toxicology·2026

Large Language Models for Clinical Narrative Processing: Methods, Applications, and Challenges.

Methods and protocols·2026

Is a tiered classification framework needed for sexually transmitted infections?

The Lancet. Infectious diseases·2026

Nucleic acid amplification testing and genome sequencing for WHO priority viruses in Africa: a scoping review.

The Lancet. Infectious diseases·2026

Ring and community vaccination for Bundibugyo virus outbreak response: a stochastic network modelling study.

The Lancet. Infectious diseases·2026

Accelerated qualification of diagnostic tests during an ongoing outbreak of Bundibugyo virus disease: a collaborative analytical validation study.

The Lancet. Infectious diseases·2026

Sepsis, endemic and emerging infectious diseases: converging concepts and clinical implications.

The Lancet. Infectious diseases·2026

Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.

The Lancet. Infectious diseases·2026

Clinical Efficacy of High-Frequency Deep Repetitive Transcranial Magnetic Stimulation in the Treatment of Depression and the Predictive Role of Baseline Triglyceride Levels: A Randomized Sham-Controlled Trial.

Clinical EEG and neuroscience·2026

Mechanistic Basis and Therapeutic Potential of a Novel TXNIP Inhibitor in Diabetes Treatment.

Journal of medicinal chemistry·2026

Discovery of BRD9 PROTAC/IMiD Bifunctional Molecules as Potent Therapeutics for Hematologic Malignancies.

Journal of medicinal chemistry·2026

First line asciminib in chronic myeloid leukemia: a quest for the "Holy Grail" of tolerability.

Haematologica·2026

Successful treatment of systemic juvenile xanthogranuloma with an ABL2::GAB2 fusion using dasatinib after failure of conventional chemotherapy and MEK inhibition.

Haematologica·2026

Repurposing MK0873 as a non-covalent hTERT-Targeting compound: a proof of concept study.

Frontiers in aging·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us